Osteoporosis News and Research

Latest Osteoporosis News and Research

UAB receives NIDCR grant to create national dental practice-based research network

Oral health has been called the window to one's overall health, and a new national research effort led by the University of Alabama at Birmingham School of Dentistry aims to provide people on the frontline of oral health care - community dentists in private practice - the opportunity to be on the forefront of research that addresses day-to-day issues they face with patients. The effort not only could improve the nation's dental health but its overall health as well.

16 Apr 2012

$Researchers identify 32 genetic regions associated with osteoporosis, fracture$

Researchers identify 32 genetic regions associated with osteoporosis, fracture

Thirty-two previously unidentified genetic regions associated with osteoporosis and fracture have been identified by a large, worldwide consortium of researchers, including Stanford Prevention Research Center chief John Ioannidis, MD, DSc. Variations in the DNA sequences in these regions confer either risk or protection from the bone-weakening disease. Many, but not all, of the regions encode proteins involved in pathways known to involve bone health.

16 Apr 2012

Study reveals genetic predictors of bone health and osteoporosis

An international consortium of researchers have identified a group of genes associated with the development of osteoporosis, a debilitating bone disease that cripples more than 10 million Americans a year and costs the U.S. healthcare system an estimated $17 billion annually.

16 Apr 2012

Asthma treatment still inadequate in Australia

Writing in the latest edition of Australian Prescriber, Associate Professor Helen Reddel, research leader at the Woolcock Institute of Medical Research says many people are prescribed higher doses than necessary. Most people do not use their inhalers correctly, leading to poor clinical outcomes and wasted medicines.

15 Apr 2012

New supplement outlines prospective surveillance model for breast cancer

A new supplement in the journal Cancer outlines an innovative model to address a wide range of physical issues faced by women with breast cancer and offers hope for improved function and full participation in life activities for patients through rehabilitation and exercise.

11 Apr 2012

Eggs developed from stem cells could change reproductive technology

Scientists have developed human egg cells that have been grown entirely in the laboratory from stem cells. These could be fertilized later this year in a development that will revolutionize fertility treatment and might even lead to a reversal of the menopause in older women.

9 Apr 2012

Nine physician organizations identify specific tests or procedures that may be unnecessary

Nine leading physician specialty societies have identified specific tests or procedures that they say are commonly used but not always necessary in their respective fields. Patient advocates are calling the move a significant step toward improving the quality and safety of health care.

4 Apr 2012

Amgen, UCB commence CDP7851/AMG 785 Phase 3 trial in postmenopausal osteoporosis

UCB and Amgen announced today the start of their sclerostin antibody (CDP7851/AMG 785) Phase 3 clinical trial program for the treatment of postmenopausal osteoporosis.

4 Apr 2012

Many RA patients more likely to develop lower GI disease

Add lower gastrointestinal (GI) problems such as ulcers, bleeding and perforations to the list of serious complications facing many rheumatoid arthritis patients. They are at greater risk for GI problems and gastrointestinal-related death than people without the disease, a Mayo Clinic study shows.

4 Apr 2012

IMS supports new guidance on glucocorticoid use

The International Osteoporosis Foundation, along with the European Society for Calcified Tissue, launched new guidance on glucocorticoid use at the European Congress on Osteoporosis and Osteoarthritis (which took place in Bordeaux from March 21 - 24, 2012). Given the special relevance to postmenopausal women, the International Menopause Society (IMS) is supporting the publication of the guidance.

31 Mar 2012

One-side parathyroid surgery has poorer long-term outcomes

Dr James Norman, MD and his partners at the Norman Parathyroid Center have published a landmark study in this week's Journal of the American College of Surgeons describing how the operation they developed and advocated for more than 19 years has significantly poorer long-term outcomes. The unilateral or "one-side" parathyroid surgical procedure to remove parathyroid tumors from patients suffering from hyperparathyroidism is a dramatic change from the large neck operation that it replaced.

29 Mar 2012

DSMB recommends Bionovo to continue Menerba Phase 3 trial for hot flashes

Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, announced today that the Company's independent Data Safety Monitoring Board (DSMB) recommended that the Phase 3 trial of Menerba (MF101) could continue as designed after an initial review of its clinical safety and tolerability data.

29 Mar 2012

ECTS, IOF publish guidance document to manage GIO

Oral glucocorticoids are commonly prescribed for a wide variety of disorders, most commonly for rheumatoid arthritis, obstructive pulmonary disease and inflammatory bowel diseases. However, the use of these medications can result in rapid bone loss during the first three to six months of therapy, leading to increased risk of fragility fractures.

28 Mar 2012

Specific precautions must be taken for individuals on longer-term oral glucocorticoid therapy

Millions of people around the world are prescribed glucocorticoids for a wide variety of inflammatory conditions, including, rheumatoid arthritis, asthma and inflammatory bowel diseases. Although they are effective and widely used, one of the potentially serious side effects of these medications is glucocorticoid-induced osteoporosis.

28 Mar 2012

Boniva generics receive FDA approval for treatment, prevention of osteoporosis

The U.S. Food and Drug Administration today approved the first generic versions of Boniva (ibandronate) tablets, a once-monthly product to treat or prevent osteoporosis in women after menopause.

27 Mar 2012

UK researcher receives IOF-Servier Young Investigator Research Grant

The IOF-Servier Young Investigator Research Grant has been awarded to Dr Mark Edwards, clinical research fellow at the MRC Lifecourse Epidemiology Unit at Southhampton General Hospital in the UK.

27 Mar 2012

Early growth predicts strength of the hip bone in childhood

Researchers from the MRC Lifecourse Epidemiology Unit, University of Southampton, have presented evidence that early growth predicts the size, mineralisation, shape and strength of the hip bone in childhood.

26 Mar 2012

Benvenue's Blazer Vertebral Augmentation System now available in the U.S.

Today Benvenue Medical, Inc., a developer of minimally invasive solutions for spine repair, launched the Blazer Vertebral Augmentation System for vertebral compression fractures (VCF) in the U.S. at the 2012 Society of Interventional Radiology (SIR) annual meeting.

26 Mar 2012

$Economic burden of fragility fractures in Europe far exceeds previous estimates$

Economic burden of fragility fractures in Europe far exceeds previous estimates

Researchers at the European Congress of Osteoporosis & Osteoarthritis in Bordeaux have presented new data * which shows that the economic burden of fragility fractures in the 27 member states of the European Union far exceeds previous estimates, with hip fractures accounting for around 55% of costs.

26 Mar 2012

Asahi Kasei announces commencement of tender offer for ZOLL

Asahi Kasei Corporation, Japan's leading diversified chemical manufacturer with businesses in the health care, chemicals & fibers, homes & construction materials, and electronics sectors, announced today the commencement of a tender offer through its indirect wholly owned U.S. subsidiary Asclepius Subsidiary Corporation for all outstanding shares of common stock of ZOLL Medical Corporation for $93 per share, net to the seller in cash, without interest and less any required withholding taxes.

26 Mar 2012